CA
NZ
UK
AU
IND
US
…
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -42.82M | -47.94M | -29.10M | -29.19M | -33.96M |
| Net income | -42.76M | -47.91M | -29.07M | -29.15M | -33.94M |
| Selling general administrative | 15.85M | 12.15M | 10.24M | 10.07M | 9.49M |
| Selling and marketing expenses | - | - | 0.29M | - | - |
| Gross profit | -0.13M | -0.15M | -0.12M | - | - |
| Reconciled depreciation | 0.14M | 0.15M | 0.10M | 0.04M | 0.05M |
| Ebit | -42.82M | -47.94M | -28.71M | -29.95M | -32.48M |
| Ebitda | -42.68M | -47.79M | -28.58M | -29.91M | -32.79M |
| Depreciation and amortization | 0.14M | 0.15M | 0.12M | 0.04M | -0.32M |
| Non operating income net other | - | - | - | 0.14M | - |
| Operating income | -49.33M | -51.52M | -33.92M | -29.91M | -32.48M |
| Other operating expenses | 49.33M | 51.52M | 33.92M | 29.91M | 32.48M |
| Interest expense | 0.00M | 0.00M | 0.39M | 0.78M | 1.20M |
| Tax provision | -0.06M | -0.03M | -0.07M | -0.04M | -0.02M |
| Interest income | 6.54M | 3.60M | 4.73M | 1.74M | 0.01M |
| Net interest income | 6.54M | 3.60M | 4.07M | 0.58M | -1.19M |
| Income tax expense | -0.06M | -0.03M | -0.03M | -0.04M | -0.02M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 49.33M | 51.52M | 33.92M | 29.91M | 32.48M |
| Cost of revenue | 0.13M | 0.15M | 0.12M | - | - |
| Total other income expense net | 6.50M | 3.58M | 4.83M | 0.72M | -1.49M |
| Net income from continuing ops | -42.76M | -47.91M | -26.75M | -29.15M | -33.94M |
| Net income applicable to common shares | - | - | - | -29.15M | -33.94M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 193.44M | 110.90M | 89.40M | 123.02M | 38.48M |
| Other current assets | 2.41M | 1.27M | 4.58M | 1.31M | 0.89M |
| Total liab | 10.20M | 11.26M | 6.86M | 15.56M | 21.40M |
| Total stockholder equity | 183.24M | 99.64M | 82.55M | 107.46M | 17.07M |
| Other current liab | 5.53M | 6.81M | 3.71M | 3.52M | 0.11M |
| Common stock | 0.13M | 0.09M | 0.07M | 0.06M | 0.03M |
| Capital stock | 0.13M | 0.09M | 0.07M | 0.06M | 0.03M |
| Retained earnings | -329.80M | -287.05M | -239.13M | -210.07M | -180.92M |
| Other liab | - | - | - | 0.00M | - |
| Other assets | - | - | 0.00M | 0.20M | 0.33M |
| Cash | 18.91M | 34.10M | 32.40M | 12.59M | 36.83M |
| Total current liabilities | 9.75M | 10.51M | 5.82M | 13.40M | 12.72M |
| Current deferred revenue | - | - | - | - | 3.81M |
| Net debt | -18.16M | -33.06M | -31.06M | -3.41M | -22.20M |
| Short term debt | 0.31M | 0.28M | 0.31M | 7.03M | 5.95M |
| Short long term debt | - | - | - | 7.00M | 5.83M |
| Short long term debt total | 0.75M | 1.03M | 1.34M | 9.18M | 14.63M |
| Other stockholder equity | 512.77M | 386.53M | 321.64M | 317.59M | 197.96M |
| Property plant equipment | - | - | - | 0.17M | 0.18M |
| Total current assets | 191.66M | 109.43M | 87.55M | 122.62M | 37.96M |
| Net tangible assets | - | - | - | 107.46M | 17.07M |
| Short term investments | 169.35M | 73.53M | 50.57M | 107.92M | - |
| Net receivables | 0.99M | 0.53M | - | - | 0.24M |
| Long term debt | - | - | - | 2.15M | 8.65M |
| Inventory | - | - | - | - | -0.24M |
| Accounts payable | 3.91M | 3.41M | 1.81M | 2.86M | 2.85M |
| Accumulated other comprehensive income | 0.15M | 0.06M | -0.03M | -0.12M | - |
| Common stock total equity | - | - | - | 0.06M | - |
| Retained earnings total equity | - | - | - | -210.07M | - |
| Non currrent assets other | 0.93M | 0.24M | 0.30M | 0.20M | 0.33M |
| Non current assets total | 1.78M | 1.47M | 1.86M | 0.40M | 0.52M |
| Capital lease obligations | 0.75M | 1.03M | 1.34M | 0.03M | 0.14M |
| Long term debt total | - | - | - | 2.15M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -94.09M | -21.53M | -1.72M | -126.22M | -107.21M |
| Change to liabilities | - | - | - | -0.63M | 0.83M |
| Total cashflows from investing activities | -94.11M | -21.53M | 59.43M | -107.37M | -107.37M |
| Net borrowings | -0.01M | -0.13M | -9.50M | -5.85M | -5.83M |
| Total cash from financing activities | 121.01M | 61.48M | -7.91M | 111.31M | 20.77M |
| Change to operating activities | - | - | - | -1.24M | 0.68M |
| Net income | -42.76M | -47.91M | -29.07M | -29.15M | -33.94M |
| Change in cash | -15.18M | 1.70M | 19.81M | -24.24M | -8.17M |
| Begin period cash flow | 34.10M | 32.40M | 12.59M | 36.83M | 45.00M |
| End period cash flow | 18.91M | 34.10M | 32.40M | 12.59M | 36.83M |
| Total cash from operating activities | -42.09M | -38.26M | -31.71M | -28.18M | -28.95M |
| Issuance of capital stock | 108.15M | 61.15M | 4.11M | 105.41M | 21.18M |
| Depreciation | 0.14M | 0.15M | 0.12M | 0.04M | 0.05M |
| Other cashflows from investing activities | 1.64M | 1.37M | - | 19.00M | - |
| Sale purchase of stock | - | - | - | 117.16M | - |
| Other cashflows from financing activities | 0.71M | 0.46M | -0.21M | 11.73M | -0.41M |
| Change to netincome | - | - | - | 2.33M | 2.84M |
| Capital expenditures | 0.01M | 0.04M | 0.14M | 0.16M | 0.16M |
| Cash flows other operating | - | - | - | -0.45M | - |
| Cash and cash equivalents changes | - | - | - | -24.24M | - |
| Change in working capital | -3.49M | 6.83M | -3.85M | -1.23M | 1.51M |
| Stock based compensation | 5.18M | 3.59M | 2.25M | 2.33M | 2.54M |
| Other non cash items | -1.17M | -0.91M | -1.17M | -0.16M | 0.97M |
| Free cash flow | -42.10M | -38.29M | -31.85M | -28.33M | -28.95M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics Inc |
-0.25 1.81% |
13.56 | - | - | - | 7.04 | -4.92 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
195 Church Street, New Haven, CT, United States, 06510
203 304 2499
34
| Name | Title | Year Born |
|---|---|---|
| Ms. Jennifer L. Good | Co-Founder, CEO, Pres & Director | 1965 |
| Dr. Thomas R. Sciascia M.D. | Co-Founder & Chief Science Officer | 1953 |
| Ms. Lisa Delfini | Chief Financial Officer | 1970 |
| Mr. Christopher Galletta | Controller & Chief Accounting Officer | 1978 |
| Katie McManus | Communications Mang. | NA |
| Mr. Farrell Simon Pharm.D. | Sr. VP and Head of Commercial & Strategy | NA |
| Dr. David J. Clark A.F.P.M., M.D., M.R.C.P. | Chief Medical Officer | 1965 |
| Ms. Danine Summers | VP of Medical Affairs | 1958 |
| Ms. Jennifer L. Good | Co-Founder, CEO, President & Director | 1965 |
| Katie McManus | Communications Manager | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...